HC Wainwright & Co. Initiates Coverage On FibroBiologics with Buy Rating, Announces Price Target of $12
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has initiated coverage on FibroBiologics with a Buy rating and set a price target of $12.

October 30, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has initiated coverage on FibroBiologics with a Buy rating and a price target of $12, indicating a positive outlook.
The initiation of coverage with a Buy rating and a specific price target of $12 by HC Wainwright & Co. suggests a positive sentiment towards FibroBiologics. This is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100